{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:17Z","timestamp":1787020997611,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced Hybrid Closed-Loop system (AHCL) has profoundly changed type 1 diabetes therapy. This study primarily aimed to assess the impact on Glycemia Risk Index (GRI) and other continuous glucose monitoring (CGM) metrics when switching from one of four insulin strategies to AHCL in type 1 adult patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective pre\/post observational study; 198 patients (age 44.4\u2009\u00b1\u200912.7\u00a0years, 115 females\/83 males, diabetes duration 24.7\u2009\u00b1\u200911.6\u00a0years, HbA1c 7.4\u2009\u00b1\u20091%), treated with different insulin therapies (MDI, CSII, SAP with PLGS, HCL) were assessed before and after switching to an AHCL (MiniMed 780G, Diabeloop Roche, Tandem Control-IQ) at 1, 3, 6, and 12\u00a0months. Mixed-effects multivariable regression models were used to estimate the mean pre\/post variations at different time points, adjusted for potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A month after the switch, there was an improvement in CGM metrics and HbA1c for all patients: GRI \u221210.7, GMI \u22120.27%, CV \u22122.1%, TAR\n                      <jats:sub>&gt;250<\/jats:sub>\n                      \u22123.7%, TAR\n                      <jats:sub>180-250<\/jats:sub>\n                      \u22125.6%, TIR\u2009+\u20099.7%, HbA1c \u22120.54% (all p\u2009&lt;\u20090.001). This improvement was maintained throughout the observational period (at 3, 6, and 12\u00a0months, with all p-values\u2009&lt;\u20090.001). When improvements across the 780, Diabeloop, and Tandem CIQ devices were compared: Diabeloop demonstrated significantly better performance in terms of GRI, GMI, CV, TAR\n                      <jats:sub>&gt;250<\/jats:sub>\n                      at T1 (for all p\u2009&lt;\u20090.01); 780 recorded highest average decrease in TAR\n                      <jats:sub>180-250<\/jats:sub>\n                      (p\u2009=\u20090.020), while Tandem achieved the most significant reduction in TBR\n                      <jats:sub>54-69<\/jats:sub>\n                      (p\u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adopting an AHCL leads to a rapid and sustained improvement in GRI and other parameters of metabolic control for up to a year, regardless of prior insulin therapies, baseline conditions or brands.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-024-01946-w","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T23:08:44Z","timestamp":1720998524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience"],"prefix":"10.1186","volume":"29","author":[{"given":"Eugenia","family":"Resmini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Vincenzo","family":"Cornaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Madaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia Chiara","family":"Pezzaioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Buoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Girelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"issue":"1","key":"1946_CR1","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1089\/dia.2009.0189","volume":"12","author":"E Renard","year":"2010","unstructured":"Renard E. Insulin pump use in Europe. Diabetes Technol Ther. 2010;12(1):S29-32. https:\/\/doi.org\/10.1089\/dia.2009.0189.","journal-title":"Diabetes Technol Ther"},{"key":"1946_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta14110","volume":"14","author":"E Cummins","year":"2010","unstructured":"Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1\u2013181. https:\/\/doi.org\/10.3310\/hta14110.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1946_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1089\/dia.2014.0242","volume":"17","author":"D Bruttomesso","year":"2015","unstructured":"Bruttomesso D, Laviola L, Lepore G, Italian Study Group on Diffusion of CSII, et al. Continuous subcutaneous insulin infusion in Italy: third national survey. Diabetes Technol Ther. 2015;17(2):96\u2013104. https:\/\/doi.org\/10.1089\/dia.2014.0242.","journal-title":"Diabetes Technol Ther"},{"key":"1946_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2021.100312","volume":"19","author":"EM Aiello","year":"2021","unstructured":"Aiello EM, Deshpande S, Ozaslan B, et al. Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations. Curr Opin Biomed Eng. 2021;19: 100312. https:\/\/doi.org\/10.1016\/j.cobme.2021.100312.","journal-title":"Curr Opin Biomed Eng"},{"key":"1946_CR5","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/jc.2010-2756","volume":"96","author":"DC Klonoff","year":"2011","unstructured":"Klonoff DC, Buckingham B, Christiansen JS, et al. Endocrine society: continuous glucose monitoring: an Endocrine Society clinical practice guideline. J ClinEndocrinol Metab. 2011;96:2968\u201379. https:\/\/doi.org\/10.1210\/jc.2010-2756.","journal-title":"J ClinEndocrinol Metab"},{"key":"1946_CR6","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4158\/EP.16.5.730","volume":"16","author":"TC Blevins","year":"2010","unstructured":"Blevins TC, Bode BW, Garg SK, AACE Continuous Glucose Monitoring Task Force, Rothermel C, et al. Statement by the American Association of clinical endocrinologists consensus panel on continuous glucose monitoring. Endocr Pract. 2010;16:730\u201345. https:\/\/doi.org\/10.4158\/EP.16.5.730.","journal-title":"Endocr Pract"},{"key":"1946_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1002853","volume":"363","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Tamborlane WT, Ahmann A, et al. STAR 3 study group: effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1002853.","journal-title":"N Engl J Med"},{"issue":"2","key":"1946_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.324","volume":"5","author":"J William","year":"2022","unstructured":"William J, McCluskey J, Gleeson N. RT-CGM in conjunction with CSII vs MDI in optimizing glycaemic control in T1DM: systemic review and meta-analysis. Endocrinol Diabetes Metab. 2022;5(2): e00324. https:\/\/doi.org\/10.1002\/edm2.324.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"5","key":"1946_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1177\/19322968221085273","volume":"17","author":"DC Klonoff","year":"2023","unstructured":"Klonoff DC, Wang J, Rodbard D, et al. A Glycemia Risk Index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol. 2023;17(5):1226\u201342. https:\/\/doi.org\/10.1177\/19322968221085273.","journal-title":"J Diabetes Sci Technol"},{"issue":"7","key":"1946_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/dia.2023.0040","volume":"25","author":"C Piona","year":"2023","unstructured":"Piona C, Marigliano M, Roncar\u00e0 C, et al. Glycemia risk index as a novel metric to evaluate the safety of glycemic control in children and adolescents with type 1 diabetes: an observational, multicentre, Real-Life Cohort Study. Diabetes Technol Ther. 2023;25(7):507\u201312. https:\/\/doi.org\/10.1089\/dia.2023.0040.","journal-title":"Diabetes Technol Ther"},{"issue":"22","key":"1946_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"8587","author":"T Battelino","year":"2022","unstructured":"Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2022;8587(22):42\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(22)00319-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1946_CR12","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1111\/dom.15208","volume":"25","author":"KE Karakus","year":"2023","unstructured":"Karakus KE, Shah VN, Klonoff D, Akturk HK. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes. Diabetes Obes Metab. 2023;25(11):3144\u201351. https:\/\/doi.org\/10.1111\/dom.15208.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1946_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/dia.2023.0261","volume":"26","author":"G Lepore","year":"2024","unstructured":"Lepore G, Borella ND, Castagna G, et al. Advanced hybrid closed-loop system achieves and maintains recommended time in range levels for up to 2 years: predictors of best efficacy. Diabetes Technol Ther. 2024;26(1):49\u201358. https:\/\/doi.org\/10.1089\/dia.2023.0261.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"1946_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/19322968221128565","volume":"18","author":"PY Benhamou","year":"2024","unstructured":"Benhamou PY, Adenis A, Tourki Y, et al. Efficacy of a hybrid closed-loop solution in patients with excessive time in hypoglycaemia: a post hoc analysis of trials with DBLG1 system. J Diabetes Sci Technol. 2024;18(2):372\u20139. https:\/\/doi.org\/10.1177\/19322968221128565.","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"1946_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1056\/NEJM200002103420603","volume":"342","author":"JM Lachin","year":"2000","unstructured":"Lachin JM, Genuth S, Cleary P, et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381\u20139. https:\/\/doi.org\/10.1056\/NEJM200002103420603.","journal-title":"N Engl J Med"},{"issue":"6","key":"1946_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421\u201331. https:\/\/doi.org\/10.7326\/0003-4819-141-6-200409210-00007.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1946_CR17","doi-asserted-by":"publisher","first-page":"e2221","DOI":"10.1210\/clinem\/dgac034","volume":"107","author":"M Yapanis","year":"2022","unstructured":"Yapanis M, James S, Craig ME, et al. Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab. 2022;107(6):e2221\u201336. https:\/\/doi.org\/10.1210\/clinem\/dgac034.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1946_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S2213-8587(22)00212-1","volume":"10","author":"P Choudhary","year":"2022","unstructured":"Choudhary P, Kolassa P, Keuthage W, ADAPT study Group, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol. 2022;10(10):720\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(22)00212-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1946_CR19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.36171\/jamd22.25.2.1","volume":"25","author":"M De Luca","year":"2022","unstructured":"De Luca M, Modestino M, Iacono O, et al. Pancreas artificiale: rassegna dei sistemi attualmente disponibili in Italia per la cura del diabete mellito di tipo 1. JAMD. 2022;25:120\u20139.","journal-title":"JAMD"},{"key":"1946_CR20","volume-title":"Applied mixed models in medicine","author":"H Brown","year":"1999","unstructured":"Brown H, Prescott R. Applied mixed models in medicine. Hoboken: Wiley; 1999."},{"issue":"3","key":"1946_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983\u201397.","journal-title":"Biometrics"},{"key":"1946_CR22","unstructured":"Linea Guida della Associazione dei Medici Diabetologi (AMD), della Societ\u00e0 Italiana di Diabetologia (SID) e della Societ\u00e0 Italiana di Endocrinologia e Diabetologia Pediatrica (SIEDP). La terapia del diabete mellito di tipo 1. 16\/03\/2022: 1\u2013432."},{"key":"1946_CR23","doi-asserted-by":"publisher","first-page":"9796019","DOI":"10.1155\/2020\/9796019","volume":"2020","author":"F Liu","year":"2020","unstructured":"Liu F, Guan Y, Li X, et al. Different effects of structured education on glycemic control and psychological outcomes in adolescent and adult patients with type 1 diabetes: a systematic review and meta-analysis. Int J Endocrinol. 2020;2020:9796019. https:\/\/doi.org\/10.1155\/2020\/9796019. (eCollection 2020).","journal-title":"Int J Endocrinol."},{"issue":"2","key":"1946_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/endrev\/bnac022","volume":"44","author":"M Phillip","year":"2023","unstructured":"Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev. 2023;44(2):254\u201380. https:\/\/doi.org\/10.1210\/endrev\/bnac022.","journal-title":"Endocr Rev"},{"issue":"10","key":"1946_CR25","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00592-022-01937-5","volume":"59","author":"G Lepore","year":"2022","unstructured":"Lepore G, Rossini A, Bellante B, et al. Switching to the Minimed\u2122 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control. Acta Diabetol. 2022;59(10):1309\u201315. https:\/\/doi.org\/10.1007\/s00592-022-01937-5.","journal-title":"Acta Diabetol"},{"key":"1946_CR26","doi-asserted-by":"publisher","first-page":"110907","DOI":"10.1016\/j.diabres.2023.110907","volume":"204","author":"G Papa","year":"2023","unstructured":"Papa G, Cannarella R, Condorelli RA, et al. Glycometabolic outcomes in adult type 1 diasbetic patients switching to closed-loop systems. Diabetes Res Clin Pract. 2023;204:110907. https:\/\/doi.org\/10.1016\/j.diabres.2023.110907.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1946_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1177\/19322968211008442","volume":"16","author":"A Thomas","year":"2022","unstructured":"Thomas A, Heinemann L. Algorithms for automated insulin delivery: an overview. J Diabetes Sci Technol. 2022;16(5):1228\u201338. https:\/\/doi.org\/10.1177\/19322968211008442.","journal-title":"J Diabetes Sci Technol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-01946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-01946-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-01946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T23:15:54Z","timestamp":1720998954000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-01946-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1946"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-01946-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved from the Local Ethical Committee of Spedali Civili di Brescia (protocol number 5828).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no financial or proprietary interests in any material discussed in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}